Can risk groups accurately predict non-sentinel lymph node metastasis in sentinel lymph node-positive endometrial cancer patients? A Turkish Gynecologic Oncology Group Study (TRSGO-SLN-004)

dc.contributor.authorAltin, Duygu
dc.contributor.authorTaskin, Salih
dc.contributor.authorTokgozoglu, Nedim
dc.contributor.authorVatansever, Dogan
dc.contributor.authorGuler, Adbul H.
dc.contributor.authorGungor, Mete
dc.contributor.authorTasci, Tolga
dc.contributor.authorTuran, Hasan
dc.contributor.authorKahramanoglu, Ilker
dc.contributor.authorYalcin, Ibrahim
dc.contributor.authorCelik, Cetin
dc.contributor.authorKose, Faruk
dc.contributor.authorOrtac, Firat
dc.contributor.authorArvas, Macit
dc.contributor.authorAyhan, Ali
dc.contributor.authorTaskiran, Cagatay
dc.contributor.pubmedID33259650en_US
dc.date.accessioned2020-12-31T09:49:33Z
dc.date.available2020-12-31T09:49:33Z
dc.date.issued2020
dc.description.abstractBackground and Objectives The purpose of this study was to find out the risk factors associated with non-sentinel lymph node metastasis and determine the incidence of non-sentinel lymph node metastasis according to risk groups in sentinel lymph node (SLN)-positive endometrial cancer patients. Methods Patients who underwent at least bilateral pelvic lymphadenectomy after SLN mapping were retrospectively analyzed. Patients were categorized into low, intermediate, high-intermediate, and high-risk groups defined by ESMO-ESGO-ESTRO. Results Out of 395 eligible patients, 42 patients had SLN metastasis and 16 (38.1%) of them also had non-SLN metastasis. Size of SLN metastasis was the only factor associated with non-SLN metastasis (p = .012) as 13/22 patients with macrometastasis, 2/10 with micrometastasis and 1/10 with isolated tumor cells (ITCs) had non-SLN metastasis. Although all 4 metastases (1.8%) among the low-risk group were limited to SLNs, the non-SLN involvement rate in the high-risk group was 42.9% and all of these were seen in patients with macrometastatic SLNs. Conclusions Non-SLN metastasis was more frequent in higher-risk groups and the risk of non-SLN metastasis increased with the size of SLN metastasis. Proceeding to complete lymphadenectomy when SLN is metastatic should further be studied as the effect of leaving metastatic non-SLNs in-situ is not known.en_US
dc.identifier.issn0022-4790en_US
dc.identifier.urihttp://hdl.handle.net/11727/5329
dc.identifier.volume2020en_US
dc.identifier.wos000595089700001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1002/jso.26310en_US
dc.relation.journalJOURNAL OF SURGICAL ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectendometrial canceren_US
dc.subjectlymph node dissectionen_US
dc.subjectlymphatic metastasisen_US
dc.subjectsentinel lymph nodeen_US
dc.titleCan risk groups accurately predict non-sentinel lymph node metastasis in sentinel lymph node-positive endometrial cancer patients? A Turkish Gynecologic Oncology Group Study (TRSGO-SLN-004)en_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: